8-K: Bausch + Lomb Reports Strong First Quarter 2024 Results, Raises Full-Year Revenue Guidance

Bausch + Lomb announced impressive first-quarter 2024 results, with revenue growth of 18% as reported and 20% on a constant currency basis, leading to an increase in full-year revenue guidance.

Summary

• Bausch + Lomb reported a total revenue of $1.099 billion for the first quarter of 2024, compared to $931 million in the same period of 2023, representing an 18% increase.
• Excluding a $20 million negative impact from foreign exchange, revenue grew by approximately 20% on a constant currency basis.
• The company experienced growth across all business segments, with Vision Care revenue at $635 million, Surgical at $197 million, and Pharmaceuticals at $267 million.
• The Pharmaceuticals segment saw the most significant growth, increasing by 66% due to the acquisition of XIIDRA and the strong launch of MIEBO.
• The company's GAAP net loss attributable to Bausch + Lomb Corporation was $167 million, compared to a $90 million loss in the first quarter of 2023.
• Adjusted EBITDA was $180 million, up from $141 million in the first quarter of 2023.
• Bausch + Lomb has raised its full-year 2024 constant currency revenue growth guidance from 12-14% to 13-15%.
• The full-year revenue range is now projected to be between $4.600 and $4.700 billion.
• Foreign exchange headwinds are now expected to negatively impact revenue by approximately $90 million for the full year, up from a previous estimate of $40 million.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with strong revenue growth and raised guidance, but the net loss and increased foreign exchange headwinds temper the overall sentiment. The company is showing good progress but still has challenges to overcome.

Positives

• The company achieved strong revenue growth across all business segments.
• The acquisition of XIIDRA and the launch of MIEBO are contributing significantly to the Pharmaceuticals segment's growth.
• The increase in Adjusted EBITDA indicates improved profitability.
• The company has raised its full-year revenue guidance, reflecting confidence in future performance.
• Cash flow from operations improved significantly, reaching $41 million compared to a $56 million loss in the same quarter last year.

Negatives

• The company reported a GAAP net loss of $167 million, which is higher than the $90 million loss in the first quarter of 2023.
• Foreign exchange headwinds are expected to negatively impact revenue by approximately $90 million for the full year, a significant increase from the previous estimate of $40 million.
• Adjusted net income decreased to $24 million from $34 million in the first quarter of 2023.
• GAAP Earnings Per Share (EPS) Basic and Diluted was ($0.48), compared to ($0.26) for the first quarter of 2023.
• Adjusted EPS was $0.07, compared to $0.10 for the first quarter of 2023.

Risks

• The company faces risks related to foreign exchange rate fluctuations, which are expected to negatively impact revenue by $90 million for the full year.
• There are risks associated with the integration of acquisitions, such as XIIDRA, and the realization of expected benefits.
• The company is subject to general economic conditions, including inflation and potential recession, which could impact revenue and margins.
• The company is exposed to risks related to the proposed spin-off from Bausch Health Companies Inc., including the possibility that the transaction may not occur or may not occur on the anticipated terms or timelines.
• There are risks related to increased levels of debt as a result of debt incurred to finance the acquisition of XIIDRA.

Future Outlook

Bausch + Lomb has raised its full-year 2024 constant currency revenue growth guidance to 13-15% and expects full-year revenue to be between $4.600 and $4.700 billion, with Adjusted EBITDA between $840 and $890 million. Foreign exchange headwinds are expected to be approximately $90 million for the full year.

Management Comments

• Brent Saunders, chairman and CEO, stated that outperformance from each business unit and solid results across geographies led to an impressive quarter.
• He also noted that key franchises continue to deliver and a focus on innovation is producing tangible results.

Industry Context

The results indicate a strong performance in the eye health market, with growth across various segments. The success of new product launches like MIEBO and the relaunch of XIIDRA highlight the company's competitive position in the dry eye category. The company's focus on innovation and expansion into new markets with products like enVista Aspire also positions them well for future growth.

Comparison to Industry Standards

• Bausch + Lomb's 20% constant currency revenue growth is strong compared to competitors in the medical device and pharmaceutical space, such as Alcon (ALC) and Johnson & Johnson Vision (JNJ), which typically see single-digit growth rates.
• The 66% growth in the Pharmaceuticals segment is particularly notable, indicating a successful acquisition and launch strategy, which is higher than the average growth in the pharmaceutical sector.
• While the company's GAAP net loss is a concern, the adjusted EBITDA growth and raised revenue guidance suggest a positive trajectory, which is in line with the performance of other companies in the medical device sector that are focused on growth and innovation.
• The company's focus on innovation and new product launches, such as enVista Aspire, is similar to strategies employed by other leading companies in the ophthalmic surgical device market, such as Carl Zeiss Meditec (AFX) and Topcon (7732.T).

Stakeholder Impact

• Shareholders will likely react positively to the strong revenue growth and raised guidance, but may be concerned about the net loss and increased foreign exchange headwinds.
• Employees may be encouraged by the company's positive performance and growth prospects.
• Customers will benefit from the company's focus on innovation and new product launches.
• Suppliers may see increased demand for their products and services due to the company's growth.
• Creditors may view the company's improved cash flow from operations as a positive sign.

Next Steps

• The company will continue to focus on the launch and uptake of new products like MIEBO and enVista Aspire.
• The company will continue to execute the relaunch strategy for XIIDRA.
• The company will monitor and manage the impact of foreign exchange headwinds.
• The company will continue to invest in innovation and R&D.

Key Dates

Keywords

Bausch + Lomb, revenue growth, financial results, eye health, XIIDRA, MIEBO, EBITDA, constant currency, pharmaceuticals, vision care, surgical, guidance